Skip to main content
OpenTrials
Completed

NCT Number: NCT02085902

Does the Use of Ropivacaine Facilitates Cholecystectomy by Laparoscopy in Ambulatory Surgery?

Since the recommendations of the French Society of Digestive Surgery 2010, cholecystectomy can be performed as outpatient surgery. This approach is difficult in many centers because of post operative pain and nausea/vomiting.

The use of postoperative morphine may be responsible for the state of nausea. The use of ropivacaine allows a reduction of the morphine consumption and thus may allow the patient to have their surgery as an outpatient.

Currently, ropivacaine is used randomly during the investigators surgeries. Initially, it was used for the infiltration holes trocar. In recent years, ropivacaine is used for the reduction of intra-abdominal postoperative pain. Its use is made of parietal surgery ( hernia ) in cholecystectomy and colonic surgery. This mode of administration is allowed to view the many publications made on this subject. Its use in the investigators daily surgery, however, has not been evaluated in ambulatory surgery.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cholecystectomy Laparoscopy

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Centre hospitalier départemental Vendée

La Roche-sur-Yon, 85925, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Programmed Cholecystectomy
  • Laparoscopy
  • Man and woman
  • ≥ 18
  • ASA 1 or 2
  • Not living alone
  • Patient receiving social security coverage
  • Signature of Informed Consent Form

Exclusion criteria

  • Cholecystectomy emergency
  • Patient minor
  • Pregnant woman (pregnancy test) or during breastfeeding
  • Conversion to laparotomy
  • Patient anticoagulant curative dose
  • Living alone
  • Patient addict
  • Peptic Ulcer
  • Refusal to enter the protocol
  • Chronic requiring analgesics long-term
  • Immunosuppression
  • Long-term Treatment with corticosteroids
  • Discovery intraoperative calculation in the bile duct
  • Contraindication to ropivacaine (see cons-indications to ropivacaine)
  • Hypersensitivity to study treatment or concomitant medications anesthesia
  • Cardiac or unbalanced epileptic patients (due to the risk of cardiovascular and neurological local anesthetics)
  • Patients ASA ≥ 3
  • Patient <50 kg

Treatment and study plan

Ropivacaine

Drug

Primary outcomes

  1. Time to discharge patient after surgery

    Time frame: 6 hours postoperative

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Departemental Vendee

Other

Registry information

Acronym: VesiRop

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Mar 13, 2014
Registry last updated
Nov 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.